Hyland's Argues Class Action Trips On State Laws Despite 'Artful Pleading'
This article was originally published in The Tan Sheet
Executive Summary
Hyland’s says a class action complaint alleging deceptive business practices and false advertising for its baby products is not suitable to represent a class of consumers outside New York. But the plaintiffs argue that the issue over class suitability should be considered during the certification stage.
You may also be interested in...
Hyland’s Score Points Asking To Dismiss Class Action, But Loses Ruling
Hyland’s fails to convince a federal court to dismiss nationwide class claims alleging false advertising of its baby products, but the judge says the two women alleging the firm made false claims about its homeopathic formulas have a “high hurdle” to demonstrate a nationwide class action.
Hyland’s Score Points Asking To Dismiss Class Action, But Loses Ruling
Hyland’s fails to convince a federal court to dismiss nationwide class claims alleging false advertising of its baby products, but the judge says the two women alleging the firm made false claims about its homeopathic formulas have a “high hurdle” to demonstrate a nationwide class action.
Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers
The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.